-
Peijia Medical Commences Clinical Study for Taurus Trio TAVR System with First Patient Enrollment
•
Peijia Medical Ltd (HKG: 9996) has announced the enrollment of the first patient in a multi-center regulatory clinical study for its transcatheter aortic valve replacement (TAVR) system, Taurus Trio. This marks a significant milestone in the development and regulatory approval process for the company’s innovative cardiac device. Study Design and…
-
RemeGen’s Novel Bispecific Antibody RC148 Receives Clinical Trial Approval
•
China-based RemeGen Ltd (SHA: 688331, HKG: 9995) has announced that it has received clinical trial approval for its novel bispecific antibody (BsAb), RC148. This development marks a significant step forward in the company’s efforts to address the complex challenges of treating multiple solid tumors. RC148 Development and Phase I Study…
-
Hainan Boao Lecheng Partners with BeiGene to Boost Medical Tourism and Biotech Innovation
•
The Hainan Boao Lecheng International Medical Tourism Pilot Zone has entered into a partnership with China-based biotech firm BeiGene (NASDAQ: BGNE). The collaboration aims to capitalize on the respective strengths of both entities to advance the translation of scientific and technological achievements, foster talent cultivation and exchange, and co-construct innovation…
-
Jiangsu Hengrui’s Camrelizumab and Apatinib Combo Accepted for FDA Review for HCC Treatment
•
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has announced that the US Food and Drug Administration (FDA) has accepted for review the Biologic License Application (BLA) for its programmed death-1 (PD-1) monoclonal antibody (mAb) camrelizumab, combined with the small-molecule targeted cancer therapy apatinib, as a first-line treatment for unresectable or…
-
Jacobio Pharma’s Glecirasib Enters Breakthrough Therapy Review for Pancreatic Cancer Treatment
•
China-based Jacobio Pharma (HKG: 1167) has announced that its novel KRAS G12C inhibitor, glecirasib, has entered into the breakthrough therapy review process for the treatment of locally advanced or metastatic pancreatic cancer with the KRAS G12C mutation. The drug is being developed as a second-line treatment in combination with gemcitabine…
-
Jiangsu Aidea’s ACC008 Demonstrates Non-Inferior Efficacy to Genvoya in Phase III HIV Study
•
Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488) has announced the summary report of a Phase III clinical study for its fixed dose preparation ainuovirine, lamivudine, tenofovir disoproxil (ACC008) as a switch therapy for previously treated HIV-1 patients. The drug was previously approved to treat treatment-naïve HIV-1 patients in China in…
-
Everest Medicines Completes Enrollment for Nefecon’s Phase III Extension Study in China
•
China-based Everest Medicines (HKG: 1952) has announced the completion of patient enrollment for the China open-label extension (cOLE) of the Phase III NefIgArd study. This cOLE study provides an additional 9 months of treatment with Nefecon to all qualifying patients who have completed the NefIgArd study, aiming to evaluate the…
-
WuXi AppTec Reports 6.28% Revenue Growth and 23.67% Net Profit Increase in H1 2023
•
China-based WuXi AppTec Co., Ltd (SHA: 603259, HKG: 2359) has released its financial report for the first half of 2023, recording revenues of RMB 18.871 billion (USD 2.6 billion), representing a 6.28% year-on-year (YOY) growth. Net profits reached RMB 4.761 billion (USD 666 million), marking a significant increase of 23.67%…
